nonspecif
effect
nse
vaccin
discuss
potenti
longterm
benefici
effect
beyond
direct
protect
specif
pathogen
coldadapt
live
attenu
influenza
vaccin
caiv
induc
local
innat
immun
respons
provid
broad
rang
antivir
immun
herein
examin
whether
donor
viru
caiv
provid
nonspecif
crossprotect
respiratori
syncyti
viru
rsv
degre
rsv
replic
significantli
reduc
administ
rsv
infect
without
rsvspecif
antibodi
respons
vaccin
induc
immedi
releas
cytokin
infiltr
leukocyt
respiratori
tract
moder
immun
perturb
caus
rsv
infect
potenc
protect
rsv
challeng
significantli
reduc
mice
confirm
signal
pathway
necessari
observ
immedi
shortterm
protect
result
suggest
caiv
provid
shortterm
nonspecif
protect
genet
unrel
respiratori
pathogen
addit
benefit
caiv
mitig
acut
respiratori
infect
vaccin
yet
avail
need
assess
futur
studi
respiratori
viral
infect
caus
influenza
viru
respiratori
syncyti
viru
rsv
human
parainfluenza
virus
hpiv
coronavirus
remain
global
public
health
concern
acknowledg
magnitud
problem
highlight
need
research
focus
prevent
respiratori
viral
infect
howev
except
influenza
viru
author
vaccin
avail
prevent
emergingreemerg
respiratori
viral
infect
hall
vaccin
base
adapt
immun
respons
provid
protect
specif
pathogen
safe
control
activ
immun
system
result
specif
memori
vaccin
host
protect
secondari
infect
pathogen
chang
et
al
recent
sever
studi
report
nonspecif
benefici
effect
vaccin
mortal
morbid
effect
explain
sole
adapt
immun
aabi
et
al
goodridg
et
al
grow
evid
show
innat
immun
system
acquir
adapt
characterist
train
immun
via
epigenet
reprogram
innat
immun
cell
blok
et
al
temporari
antivir
respons
could
also
establish
turnov
cell
surviv
initi
infect
hamilton
et
al
nonspecif
effect
nse
vaccin
usual
develop
suffici
durat
initi
vaccin
possibl
remain
howev
nse
may
also
oper
immedi
manner
shortterm
protect
especi
consid
potent
antivir
respons
innat
immun
system
takeuchi
akira
effect
expect
quit
signific
especi
live
attenu
vaccin
mimic
natur
infect
seo
et
al
exampl
live
influenza
vaccin
found
associ
immedi
indirect
protect
respiratori
ill
among
children
piedra
et
al
main
caus
respiratori
infect
influenza
viru
respons
season
epidem
well
occasion
pandem
worldwid
high
socioeconom
medic
burden
turner
et
al
among
variou
type
vaccin
coldadapt
live
attenu
influenza
vaccin
caiv
elicit
strong
mucos
immun
respons
respiratori
tract
provid
effect
immun
infect
renegar
et
al
distinct
current
licens
flumist
r
altern
independ
caiv
base
backbon
describ
baez
et
al
genet
basi
attenu
character
variou
caiv
season
influenza
highli
pathogen
avian
influenza
hpai
pandem
evalu
jang
et
al
jang
et
al
jang
et
al
caiv
provid
immedi
broad
spectrum
protect
heterosubtyp
heterotyp
influenza
virus
seo
et
al
jang
et
al
examin
whether
provid
nonspecif
immedi
crossprotect
rsv
despit
classifi
distinct
viral
famili
latiff
et
al
rsv
influenza
share
common
featur
term
pathogenesi
virus
caus
acut
respiratori
infect
initi
infect
trigger
innat
immun
via
patternrecognit
receptor
prr
includ
retino
acidinduc
gene
rigi
diebold
et
al
guillot
et
al
marr
et
al
activ
prr
induc
product
interferon
ifn
proinflammatori
cytokin
chemokin
iwasaki
pillai
induc
robust
antivir
immunomodulatori
respons
interfer
viru
replic
spread
gonzaleznavaja
et
al
durbin
et
al
also
critic
viral
clearanc
influenza
viru
rsv
weiss
et
al
eiching
et
al
found
mous
infect
model
earli
innat
immun
respons
elicit
respiratori
tract
restrict
rsv
replic
amelior
rapid
increas
earli
inflammatori
cytokin
follow
rsv
challeng
import
pathway
confirm
use
knockout
ko
mice
consid
previou
find
longterm
effect
influenza
infect
subsequ
rsv
exposur
walzl
et
al
discuss
immedi
nse
caiv
addit
benefit
vaccin
among
infant
prevent
acut
respiratori
infect
sixweekold
femal
balbc
mice
purchas
orient
bio
inc
seoul
south
korea
mice
balbc
background
provid
kangwon
nation
univers
south
korea
mice
maintain
specificpathogenfre
spf
condit
anim
studi
perform
four
mice
per
group
n
except
mice
n
anim
experi
conduct
accord
institut
anim
madindarbi
canin
kidney
mdck
atcc
manassa
va
unit
state
cell
cultur
minim
essenti
medium
mem
hyclon
south
logan
ut
unit
state
contain
fetal
bovin
serum
fb
hyclon
propag
allanto
caviti
embryon
egg
titrat
use
plaqu
assay
use
mdck
cell
c
rsv
propag
cell
atcc
previous
describ
lee
chang
viru
titer
determin
cell
use
standard
plaqu
assay
briefli
serial
dilut
rsv
stock
made
serumfre
mem
inocul
cell
plate
incub
min
c
supernat
discard
ml
agarosegrowth
media
mixtur
ad
well
agar
turn
solid
plate
incub
day
c
visual
plaqu
ml
agaros
contain
neutral
red
ad
incub
h
c
plaqu
count
mckimmbreschkin
sixweekold
femal
mice
anesthet
intramuscular
infect
alfaxalon
alfaxan
jurox
rutherford
nsw
australia
intranas
infect
viru
suspens
pfu
rsv
intraperiton
infect
formalin
inactiv
influenza
viru
inactiv
retroorbit
bleed
perform
collect
sera
immun
mice
igg
igm
antibodi
titrat
mice
euthan
bronchoalveolar
lavag
bal
fluid
obtain
wash
airway
ml
pb
bal
cell
supernat
separ
centrifug
bal
fluid
use
titrat
mucos
iga
antibodi
cytokin
level
collect
bal
cell
use
investig
immun
cell
recruit
bal
cell
count
use
hemocytomet
whole
lung
homogen
lung
supernat
cell
collect
centrifug
lung
supernat
use
viral
titrat
collect
lung
cell
use
investig
immun
cell
recruit
bal
lung
cell
count
use
hemocytomet
rsv
challeng
mice
euthan
lung
singlecel
suspens
obtain
pass
lung
tissu
cell
strainer
serumfre
mem
supernat
collect
centrifug
lung
viral
titrat
perform
use
standard
plaqu
assay
cell
lung
viral
titer
express
pfug
lung
tissu
limit
detect
pfug
level
rsv
g
f
sino
biolog
tongzhou
qu
beij
china
proteinspecif
antibodi
determin
elisa
plate
coat
pfuwel
ngwell
rsv
g
f
protein
c
overnight
block
wash
plate
incub
twofold
dilut
sera
bal
fluid
h
room
temperatur
rt
wash
plate
incub
hrpconjug
secondari
goat
antimous
iga
igg
igm
antibodi
bethyl
montgomeri
tx
unit
state
h
rt
follow
wash
incub
tmb
substrat
solut
bd
bioscienc
san
jose
ca
unit
state
min
rt
dark
colorimetr
reaction
stop
ad
h
solut
absorb
measur
nm
use
micropl
reader
concentr
measur
use
elisa
kit
pbl
piscataway
nj
unit
state
level
bal
fluid
determin
use
magnet
luminex
perform
assay
multiplex
kit
r
system
minneapoli
mn
unit
state
experi
conduct
follow
manufactur
protocol
analyz
immun
cell
popul
bal
lung
cell
incub
rat
antimous
bd
bioscienc
block
antibodi
min
rt
bal
cell
stain
biolegend
san
diego
ca
unit
state
antisiglecf
bd
bioscienc
bd
bioscienc
antimhcii
ebiosci
san
diego
ca
unit
state
biolegend
biolegend
ebiosci
biolegend
ebiosci
dapi
biolegend
biolegend
antibodi
min
c
dark
lung
cell
also
stain
biolegend
biolegend
biolegend
biolegend
antibodi
min
c
dark
place
stain
cell
fix
fac
lyse
solut
bd
bioscienc
analyz
bd
lsr
fortessa
bd
bioscienc
flow
cytometri
data
analyz
flowjo
softwar
treestar
inc
ashland
unit
state
gate
strategi
immun
cell
popul
describ
supplementari
figur
valu
express
mean
cohort
error
bar
indic
standard
deviat
sd
student
ttest
use
compar
two
group
oneway
analysi
varianc
anova
dunnett
correct
perform
compar
two
group
p
consid
statist
signific
confirm
safeti
caiv
mice
inject
plaqueform
unit
pfu
monitor
weight
chang
daili
week
infect
result
appreci
weight
loss
sign
virul
figur
mice
vaccin
pfu
variou
time
interv
prior
rsv
challeng
weight
chang
observ
day
rsv
challeng
mice
euthan
day
postchalleng
pc
collect
lung
tissu
mice
vaccin
day
rsv
challeng
present
approxim
weight
loss
day
pc
wherea
mice
group
lose
bodi
weight
figur
indic
sign
ill
reduc
activ
ruffl
fur
notic
vaccin
group
control
group
without
vaccin
lung
viral
titer
drop
threshold
level
upon
immun
prevent
rsv
replic
lung
day
interv
immun
rsv
challeng
figur
pulmonari
viral
titer
gradual
increas
interv
day
contrast
lung
viral
titer
mice
vaccin
formalininactiv
day
rsv
challeng
similar
unvaccin
mice
figur
rsv
titer
measur
cell
lung
viral
titer
parallel
immun
without
rsv
challeng
detect
level
within
day
immun
data
shown
togeth
result
demonstr
vaccin
could
confer
earli
shortterm
protect
rsv
challeng
mice
antibodi
level
mice
immun
determin
vaccin
pfu
bal
fluid
sera
obtain
mice
variou
day
postvaccin
pv
level
iga
deriv
bal
fluid
igg
igm
deriv
serum
analyz
elisa
specif
figur
iga
level
detect
level
within
day
pv
increas
rapidli
day
figur
igg
level
detect
earli
day
increas
rapidli
thereaft
figur
safeti
protect
efficaci
rsv
challeng
mice
n
per
group
vaccin
pfu
weight
chang
observ
daili
week
b
c
mice
n
per
group
vaccin
pfu
rsv
vac
vac
vac
vac
vac
day
interv
nonvaccin
vac
mice
infect
pfu
rsv
bodi
weight
monitor
daili
b
lung
viral
titer
determin
plaqu
assay
day
pc
c
mice
n
per
group
vaccin
formalininactiv
challeng
pfu
rsv
day
later
fi
vac
nonvaccin
mice
infect
pfu
rsv
vac
lung
viral
titer
determin
plaqu
assay
day
pc
dot
line
repres
limit
detect
pfug
lung
tissu
p
p
compar
vac
control
group
figur
igm
antibodi
rapidli
produc
peak
day
pv
figur
mice
immun
twice
interv
acquir
antibodi
elisa
bal
fluid
sera
collect
mice
group
present
od
valu
similar
control
group
pb
group
rsv
g
f
protein
major
protect
antigen
figur
contrast
mice
infect
rsv
rsv
group
schedul
show
strong
reactiv
rsv
g
f
protein
note
vaccin
prior
infect
rsv
appreci
chang
cell
composit
lung
supplementari
figur
lack
crossreact
rsv
even
boost
immun
suggest
immedi
protect
provid
antibodymedi
mice
vaccin
protect
rsv
challeng
without
specif
antibodi
respons
hypothes
prophylact
effect
associ
innat
immun
respons
seo
et
al
bal
fluid
cell
obtain
daili
day
mice
infect
pfu
sampl
use
examin
level
ifn
proinflammatori
cytokin
number
immun
cell
pdc
nk
cell
eosinophil
marker
innat
immun
respons
figur
concentr
peak
day
pv
decreas
gradual
wherea
induct
delay
level
peak
day
pv
figur
immun
induc
lower
still
distinctli
elev
level
popul
variou
immun
cell
type
examin
fluorescenceactiv
cell
sort
fac
analysi
figur
c
number
cell
left
side
percentag
total
immun
cell
right
side
vaccin
mice
elicit
pdc
low
cell
control
group
throughout
day
examin
peak
valu
day
pv
figur
recruit
nk
cell
cell
eosinophil
siglecf
cell
slightli
delay
show
peak
level
day
pv
number
immun
cell
bal
greatli
increas
compar
pb
control
day
pv
figur
pdc
nk
cell
show
similar
pattern
number
percentag
total
immun
cell
wherea
eosinophil
present
differ
pattern
figur
result
probabl
reflect
highest
increas
total
immun
cell
day
pv
figur
number
proport
am
siglecf
cell
figur
antibodi
mice
vaccin
ac
mice
n
per
group
vaccin
pfu
euthan
day
pv
collect
bal
fluid
sera
elisa
perform
use
pfuwel
bal
fluid
dilut
sera
dilut
b
c
di
mice
n
per
group
infect
pfu
rsv
pb
neg
control
boost
dose
interv
elisa
conduct
use
ngwell
rsv
g
protein
coat
antigen
bal
fluid
dilut
sera
dilut
e
f
elisa
rsv
f
protein
ngwell
perform
bal
fluid
dilut
g
sera
dilut
h
od
optic
densiti
p
p
compar
pb
control
group
neutrophil
inter
high
cell
also
examin
describ
figur
supplementari
figur
howev
vaccin
show
signific
differ
compar
control
overal
vaccin
induc
distinct
marker
cytokin
immun
cell
associ
innat
immun
examin
caus
reduct
rsv
replic
follow
vaccin
figur
mice
inocul
follow
rsv
challeng
day
pv
bal
fluid
lung
sampl
collect
daili
day
rsv
challeng
examin
lung
viral
titer
cytokin
level
immunecel
subset
figur
expect
contrast
nonvaccin
control
mice
present
extens
viral
growth
pfug
rsv
fail
replic
lung
mice
figur
vaccin
induc
dramat
chang
cytokin
profil
notabl
level
strongli
elev
rsv
infect
greatli
reduc
vaccin
figur
contrast
level
remain
extrem
low
rsv
infect
strongli
elev
vaccin
moreov
level
maintain
day
contrast
sharp
figur
cytokin
level
immun
cell
composit
vaccin
ac
mice
n
per
group
vaccin
pfu
bal
fluid
collect
daili
day
bal
fluid
mean
concentr
determin
elisa
level
measur
luminex
dot
line
repres
limit
detect
pgml
respect
investig
immun
cell
subset
cell
obtain
bal
stain
fluoresc
antibodi
present
method
analyz
flow
cytometri
b
c
p
p
compar
pb
control
group
decreas
day
nonvaccin
mice
thu
vaccin
prior
infect
rsv
dramat
chang
cytokin
profil
suppress
rsv
infect
note
day
rsv
challeng
figur
correspond
day
vaccin
figur
consid
interv
vaccin
challeng
remark
cytokin
profil
level
mice
rel
constant
without
notabl
perturb
follow
infect
rsv
popul
variou
immun
cell
type
also
examin
fac
analysi
figur
number
immun
cell
ie
pdc
low
cell
nk
cell
cell
consist
higher
vaccin
mice
unvaccin
mice
except
eosinophil
siglecf
cell
day
pc
figur
howev
nk
cell
eosinophil
show
differ
pattern
number
proport
total
immun
cell
probabl
reflect
increas
total
immun
cell
upon
vaccin
figur
number
proport
am
siglecf
cell
neutrophil
inter
high
cell
also
examin
describ
figur
supplementari
figur
number
percentag
am
higher
vaccin
mice
unvaccin
mice
day
pc
vaccin
mice
number
neutrophil
consist
higher
unvaccin
mice
proport
show
signific
differ
two
group
result
show
vaccin
recruit
larg
number
immun
cell
respiratori
tract
stabil
immun
environ
suffici
overcom
immun
perturb
subsequ
infect
mainten
antivir
statu
immun
probabl
respons
success
inhibit
rsv
stabil
immun
aggrav
rsv
infect
vaccin
pfu
challeng
pfu
rsv
day
later
vac
nonvaccin
mice
infect
pfu
rsv
vac
rsv
challeng
lung
bal
fluid
obtain
daili
day
lung
viral
titer
determin
plaqu
assay
bal
fluid
level
determin
elisa
mean
concentr
measur
luminex
b
dot
line
repres
limit
detect
pgml
respect
investig
immun
cell
subset
flow
cytometri
analysi
cell
obtain
bal
perform
figur
c
c
p
p
compar
vac
control
group
protect
efficaci
mice
investig
contribut
innat
immun
earli
protect
transgen
mice
defici
employ
diebold
et
al
guillot
et
al
doubl
knockout
ko
mice
immun
infect
rsv
day
pv
level
rsv
replic
lung
measur
figur
control
wild
type
wt
mice
treat
condit
figur
wherea
vaccin
caus
complet
viral
clearanc
lung
rsvinfect
wt
mice
rsv
replic
persist
ko
mice
despit
vaccin
togeth
result
suggest
innat
immun
play
import
role
earli
protect
rsv
infect
use
sever
report
discuss
nonspecif
benefici
effect
vaccin
mortal
morbid
associ
figur
protect
efficaci
balbc
mice
vaccin
rsv
challeng
knockout
ko
mice
n
per
group
b
wildtyp
wt
mice
n
per
group
vaccin
pfu
challeng
pfu
rsv
day
later
vac
nonvaccin
anim
infect
pfu
rsv
vac
lung
viral
titer
determin
plaqu
assay
use
lung
supernat
obtain
mice
euthan
day
pc
dot
line
repres
limit
detect
pfug
lung
tissu
p
compar
vac
control
group
unrel
infect
aabi
et
al
train
innat
immun
propos
underli
mechan
longterm
nse
vaccin
netea
et
al
blok
et
al
consid
substanti
reduct
allcaus
mortal
live
attenu
vaccin
eg
oral
polio
vaccin
opv
measl
vaccin
emphas
need
studi
nse
vaccin
author
mina
et
al
howev
potenti
shortterm
effect
vaccin
explor
date
previou
studi
immedi
indirect
protect
respiratori
ill
observ
part
clinic
evalu
live
influenza
vaccin
among
children
piedra
et
al
hypothes
strong
innat
immun
respons
elicit
live
attenu
vaccin
may
contribut
nonspecif
shortterm
protect
unrel
pathogen
studi
evalu
innat
immun
respons
induc
role
protect
genet
unrel
rsv
infect
mous
infect
model
provid
immedi
protect
rsv
infect
antibodyindepend
manner
mous
model
vaccin
stimul
product
marker
cytokin
day
examin
recruit
relev
immun
cell
cytokin
profil
immun
cell
rel
unperturb
maintain
even
rsv
challeng
experi
ko
mice
confirm
innat
immun
mediat
respons
rsv
protect
result
demonstr
administr
prior
rsv
challeng
activ
much
milder
distinct
induct
cytokin
recruit
immun
cell
innat
immun
respons
confer
earli
protect
rsv
infect
previous
influenza
infectionmedi
protect
rsv
evalu
mice
longlast
influenc
subsequ
respons
addit
infect
observ
walzl
et
al
contrast
present
analys
address
immedi
respons
rather
prolong
delay
respons
upon
influenza
vaccin
rather
infect
present
result
train
innat
immun
arm
suggest
indirect
nonspecif
protect
oper
wide
spectrum
innat
immun
play
import
role
initi
primari
defens
mechan
later
adapt
immun
takeuchi
akira
notabl
pandem
vaccin
provid
heterolog
well
heterosubtyp
protect
season
influenza
jang
et
al
addit
role
adapt
immun
respons
broad
protect
master
strain
confer
immedi
broadspectrum
protect
heterotyp
influenza
b
infect
seo
et
al
previous
prolong
proinflammatori
cytokin
express
influenza
vaccin
impact
innat
adapt
respons
note
live
attenu
influenza
vaccin
laiv
lanthier
et
al
mohanti
et
al
studi
show
innat
respons
potent
enough
provid
indirect
protect
immunolog
unrel
rsv
infect
albeit
within
narrow
window
vaccin
infect
figur
iga
igg
antibodi
level
low
within
day
vaccin
figur
b
contrast
high
level
igm
respons
observ
within
day
vaccin
figur
respons
rsv
surfac
protein
g
f
protein
low
pb
control
contrast
robust
respons
viru
figur
lack
crossreact
influenza
rsv
antigen
suggest
observ
crossprotect
antibodymedi
crossreact
antigennonspecif
cell
immun
appear
contribut
immedi
defens
provid
vaccin
prior
infect
rsv
alter
composit
cell
lung
supplementari
figur
vaccin
elev
product
marker
cytokin
compar
level
negativecontrol
mice
figur
level
type
ifn
significantli
lower
rsvinfect
mice
figur
although
threshold
concentr
requir
inhibit
viral
replic
difficult
assess
cytokin
level
produc
vaccin
suffici
clear
rsv
lung
figur
notabl
rsv
challeng
significantli
alter
cytokin
profil
mice
figur
suggest
immun
activ
maintain
mild
antivir
state
mice
protect
acut
perturb
cytokin
level
induc
rsv
challeng
proper
innat
respons
lead
viral
clearanc
wherea
imbalanc
respons
result
acut
respiratori
distress
han
ulevitch
thu
prior
vaccin
stabli
maintain
immun
environ
mucos
area
allevi
patholog
organ
dysfunct
caus
overreact
inflammatori
respons
induc
respiratori
infect
immun
recruit
leukocyt
immun
cell
pdc
nk
cell
respiratori
tract
directli
associ
rsv
clearanc
figur
although
vaccin
alon
affect
composit
am
supplementari
figur
number
am
also
increas
rsv
inocul
interv
supplementari
figur
cell
associ
innat
adapt
immun
colonna
et
al
mobil
nasal
mucosa
rsv
infect
gill
et
al
particular
pdc
number
percentag
elev
vaccin
mice
compar
unvaccin
control
consist
role
pdc
viru
clearanc
prevent
excess
immunopatholog
smit
et
al
wang
et
al
result
suggest
immunizationinduc
increas
pdc
play
crucial
role
viral
clearanc
addit
pdc
mention
nk
cell
also
expect
key
compon
innat
immun
inhibit
rsv
replic
direct
antivir
effect
mediat
could
attenu
rsv
replic
wheelock
bukreyev
et
al
rsv
challeng
significantli
alter
cytokin
profil
mice
figur
highli
induc
maintain
sever
day
vaccin
figur
therebi
play
import
role
shortterm
viral
clearanc
moreov
nk
cell
associ
viral
clearanc
earli
phase
rsv
infect
harker
et
al
probabl
also
play
role
immedi
protect
studi
reflect
increas
nk
cell
vaccin
figur
detail
studi
eg
ko
mice
deplet
specif
immun
cell
requir
identifi
major
compon
involv
respons
respiratori
epitheli
cell
signal
pathway
directli
contribut
innat
immun
influenza
viru
guillot
et
al
previous
demonstr
agonist
alon
induc
protect
immun
respons
combin
agonist
achiev
immedi
complet
protect
lethal
influenza
infect
seo
et
al
vaccin
ko
mice
fail
inhibit
rsv
replic
figur
confirm
innat
immun
respons
link
pathway
respons
crossprotect
rsv
notabl
rsv
replic
elev
fulli
recov
vaccin
mice
despit
defici
figur
prr
rigi
koyama
et
al
may
still
oper
ko
mice
partial
compens
impair
innat
immun
clearli
innat
immun
respons
stimul
caiv
protect
mucos
respiratori
tract
rsv
infect
potenti
safeti
issu
vaccin
merit
discuss
reflect
lung
viral
titer
rsv
replic
significantli
inhibit
prior
inocul
within
day
figur
observ
inhibit
achiev
without
signific
chang
weight
loss
day
howev
notic
chang
weight
loss
appar
shorter
interv
day
figur
despit
enhanc
inhibit
rsv
figur
previous
shown
increas
recruit
nk
cell
involv
viral
clearanc
also
weight
loss
harker
et
al
howev
appar
advers
effect
increas
nk
cell
popul
figur
could
counterbalanc
potenti
benefici
effect
associ
chang
cytokin
profil
instanc
decreas
type
ifn
prior
vaccin
figur
may
reduc
potenti
advers
effect
increas
suscept
secondari
bacteri
infect
li
et
al
prior
vaccin
rsv
challeng
transient
increas
number
eosinophil
neutrophil
figur
supplementari
figur
may
respons
complex
inflammatori
respons
underli
observ
weight
loss
vaccinationchalleng
schedul
figur
generaliz
find
limit
howev
lack
relev
anim
model
influenza
rsv
superinfect
present
result
base
attenu
strain
use
gener
caiv
season
prepandem
potenti
univers
vaccin
seo
et
al
jang
et
al
jang
et
al
jang
et
al
jang
et
al
note
flumist
r
prototyp
caiv
licens
vaccin
individu
year
age
genet
mutat
caiv
attenu
virul
intern
gene
snyder
et
al
klimov
et
al
jang
et
al
caiv
could
attenu
addit
mutat
either
surfac
antigen
intern
gene
liedmann
et
al
could
improv
safeti
profil
caiv
infant
major
distinct
two
attenu
strain
flumist
r
base
strain
baez
et
al
maassab
debord
wherea
base
backbon
lee
et
al
would
interest
determin
therefor
whether
similar
nonspecif
protect
provid
licens
caiv
vaccin
current
possibl
primeboosttyp
earli
childhood
vaccin
debat
view
implement
univers
vaccin
program
krammer
pales
futur
prospect
use
caiv
infant
subject
safeti
issu
associ
live
vaccin
addit
benefit
may
anticip
especi
nonspecif
protect
rsv
respiratori
virus
hpiv
licens
vaccin
avail
hall
present
studi
base
mous
model
present
potenti
limit
lack
common
anim
infect
model
among
differ
viru
famili
would
interest
determin
whether
observ
nonspecif
protect
could
extend
repertoir
respiratori
virus
includ
merscoronaviru
merscov
recent
pose
global
public
threat
breban
et
al
choi
moreov
nse
vaccin
evalu
clinic
set
monitor
longterm
kandasami
et
al
independ
studi
shortterm
nse
vaccin
would
impract
clinic
set
could
implement
evalu
clinic
effect
vaccin
piedra
et
al
signific
nse
observ
experiment
anim
infect
remain
explor
yl
jl
bs
design
studi
analyz
data
wrote
manuscript
yl
jl
conduct
research
studi
yj
su
provid
technic
assist
caiv
ko
mice
respect
jc
provid
scientif
advic
rsv
infect
protect
bs
supervis
experi
well
prepar
manuscript
work
support
grant
ministri
health
welfar
ministri
agricultur
food
rural
affair
mafra
korean
govern
